share_log

昆药集团(600422.SH):KPC-149口服溶液药品临床试验申请获受理

Kunming Pharmaceutical Group (600422.SH): KPC-149 oral solution drug clinical trial application accepted

Zhitong Finance ·  Jan 23 17:15

Kunming Pharmaceutical Group (600422.SH) issued an announcement. The company recently received the “Subject...” issued by the State Drug Administration

Zhitong Financial App News, Kunming Pharmaceutical Group (600422.SH) issued an announcement. The company recently received the “Notice of Acceptance” issued by the State Drug Administration. The company's drug clinical trial application for Class 2.2 improved new drug KPC-149 oral solution (acceptance numbers: CXHL2400095 and CXHL2400096, “this new drug” for short) has been accepted by the State Drug Administration.

KPC-149 oral solution is a Class 2.2 improved new drug developed by the company. The indications are: relief and prevention of acute attacks of gout; familial Mediterranean fever. According to Zhongkang data, the sales volume of gout/hyperuricemia in domestic hospitals and retail terminals in 2022 was about 2.1 billion yuan. Up to now, the company has invested a total of RMB 11.8735 million in R&D of KPC-149 oral solution.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment